Non-selective GR antagonist Mifepristone was officially approved for treatment in patients with Cushing’s syndrome [45] while another new GR inhibitor, Relacorilant (CORT125134), is under clinical investigation for its use in this group of patients [46]. The gene discussed is NR3C1; the disease is Cushing syndrome due to macronodular adrenal hyperplasia.